Mycobacterium chelonae

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 2778 Experts worldwide ranked by ideXlab platform

Marion J Skalweit - One of the best experts on this subject based on the ideXlab platform.

  • ibrutinib therapy and Mycobacterium chelonae skin and soft tissue infection
    Open Forum Infectious Diseases, 2018
    Co-Authors: Khalid M Dousa, Ahmed Babiker, Daniel Van Aartsen, Neel Shah, Robert A Bonomo, John L Johnson, Marion J Skalweit
    Abstract:

    : Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.

Michael C. Bach - One of the best experts on this subject based on the ideXlab platform.

Yoon Hoh Kook - One of the best experts on this subject based on the ideXlab platform.

  • Description of Mycobacterium chelonae subsp. bovis subsp. nov., isolated from cattle (Bos taurus coreanae), emended description of Mycobacterium chelonae and creation of Mycobacterium chelonae subsp. chelonae subsp. nov.
    International journal of systematic and evolutionary microbiology, 2017
    Co-Authors: Byoung Jun Kim, Ga Na Kim, Boram Kim, Che Ok Jeon, Joseph Jeong, Seon Ho Lee, Ji Hun Lim, Seung Heon Lee, Chang Ki Kim, Yoon Hoh Kook
    Abstract:

    Three rapidly growing mycobacterial strains, QIA-37T, QIA-40 and QIA-41, were isolated from the lymph nodes of three separate Korean native cattle, Hanwoo (Bos taurus coreanae). These strains were previously shown to be phylogenetically distinct but closely related to Mycobacterium chelonae ATCC 35752T by taxonomic approaches targeting three genes (16S rRNA, hsp6 and rpoB) and were further characterized using a polyphasic approach in this study. The 16S rRNA gene sequences of all three strains showed 99.7 % sequence similarity with that of the M. chelonae type strain. A multilocus sequence typing analysis targeting 10 housekeeping genes, including hsp65 and rpoB, revealed a phylogenetic cluster of these strains with M. chelonae . DNA–DNA hybridization values of 78.2 % between QIA-37T and M. chelonae indicated that it belongs to M. chelonae but is a novel subspecies distinct from M. chelonae . Phylogenetic analysis based on whole-genome sequences revealed a 95.44±0.06 % average nucleotide identity (ANI) value with M. chelonae , slightly higher than the 95.0 % ANI criterion for determining a novel species. In addition, distinct phenotypic characteristics such as positive growth at 37 °C, at which temperature M. chelonae does not grow, further support the taxonomic status of these strains as representatives of a novel subspecies of M. chelonae . Therefore, we propose an emended description of Mycobacterium chelonae , and descriptions of M. chelonae subsp. chelonae subsp. nov. and M. chelonae subsp. bovis subsp. nov. are presented; strains ATCC 35752T(=CCUG 47445T=CIP 104535T=DSM 43804T=JCM 6388T=NCTC 946T) and QIA-37T (=KCTC 39630T=JCM 30986T) are the type strains of the two novel subspecies.

Donald E. Craven - One of the best experts on this subject based on the ideXlab platform.

Khalid M Dousa - One of the best experts on this subject based on the ideXlab platform.

  • ibrutinib therapy and Mycobacterium chelonae skin and soft tissue infection
    Open Forum Infectious Diseases, 2018
    Co-Authors: Khalid M Dousa, Ahmed Babiker, Daniel Van Aartsen, Neel Shah, Robert A Bonomo, John L Johnson, Marion J Skalweit
    Abstract:

    : Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.